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Abstract
Recent research shows that the number of diseases associated with obesity has been increasing. In obese persons,
association with functional constipation is noted in 24.0% of cases, and obesity is recorded in 60.0% of patients with functional
constipation. Among the possible mechanisms for the development of such a combination are changes in serotonin level in
the blood, although the existing data are ambiguous and sometimes controversial.
The objective of the study is to investigate the changes in serotonin level in the blood of obese patients in combination with
constipation and its relationship with the lipid profile of the blood.
Materials and methods. 63 patients with obesity in combination with irritable bowel syndrome with constipation (IBSc),
24 patients with normal body mass index and 10 practically healthy people were examined. 25 patients with obesity and
constipation had a body mass index of 32.8±0.24kg/m2, 28 patients - 37.8±kg/m2, and 10 patients - 42.6±0.5kg/m2. In
patients with irritable bowel syndrome without obesity, the body mass index was 21.7±0.4kg/m2. The blood serotonin level
and lipid profile of the blood was determined in all patients.
Results. It was deermined that in case of irritable bowel syndrome with constipation, serotonin level in the blood was reduced.
In obesity with IBSc, the concentration of serotonin, on the contrary, was elevated. All patients with IBSc and obesity were
marked an elevated level of total cholesterol and triglycerides. A direct correlation between high levels of triglycerides and
serotonin concentration in serum of such comorbid patients was detected. The increase in the degree of obesity in the
presence of IBSc was accompanied by a decrease in the concentration of cholesterol of high density lipoprotein. Patients
with IBSc without excessive body weight had no such deviations.
Conclusions. With an increase in the degree of obesity, serotonin level in the blood increases and the lipid blood spectrum
worsens.
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Problem statement and analysis of the
recent research
Obesity is characterized by varying degrees of excess body
weight and is associated with an increase in morbidity from
other organs and systems. According to Global Burden of Dis-
ease Study, the global prevalence of overweight and obesity
in the world in the three prior decades has grown by 27.5%
for adults and 47.1% for children [14]. Most often, obesity
is diagnosed in US residents, 34% of whom are overweight,
and 27% are obese [12]. In Europe, according to the project
of multinational monitoring of trends and factors in the de-
velopment of cardiovascular diseases, obesity and associated
metabolic syndrome affects 15% of men and 24% of women,
and every 10 years prevalence Obesity is increasing by 10-
40% in most European countries [32]. According to Cerhan
J.R. et al., Ogden CL et al. [10, 25] in the United States, the
annual direct and indirect costs associated with the treatment
of obesity and its consequences were about $ 215 million [28].
In Ukraine, according to the study of 20 risk factors in
the urban population of the city of Dnipro, based on 5 outpa-
tient clinics, it was found that only 29.3% of the population
had normal body mass, and 70.7% had excess body weight
and obesity of I-III degrees [21]. Among people with exces-
sive body weight, obesity of the I degree was diagnosed in
22.75%, the II - in 7.68%, and III - in 1.03% of the subjects
[22]. The high prevalence of obesity is due to urbanization,
decreased physical activity, high caloric intake of food, de-
pression due to poor evaluation of its appearance, negative
emotional responses to diet.
Recent research shows that the number of diseases associ-
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ated with obesity is increasing. Along with violations of lipid
and carbohydrate metabolism, the development of insulin re-
sistance and type 2 diabetes, arterial hypertension, ischemic
heart disease, the organs of the gastrointestinal tract are often
involved in the process. Among these diseases, dyskinesia
of the large intestine with constipation syndrome, divertic-
ular disease, and polyposis of the colon are common. [26].
According to vd Baan-Slootweg O.H. et al [37] in obese per-
sons, functional constipation, diagnosed according to Rome
criteria III, is noted in 24% of cases, and obesity is recorded
in 60.0% of patients with functional constipation. Animal
experiments have shown that exogenous obesity associated
with constipation is accompanied by slow passage of intesti-
nal contents, although the mechanisms of this phenomenon
remain unclear, and one of them is likely to be a decrease in
the bioavailability of serotonin in the large intestine [23, 33].
Data from epidemiological studies indicates a relationship of
obesity with functional disorders of the gastrointestinal tract,
including irritable bowel syndrome, functional dyspepsia, ab-
dominal pain [27]. With regard to the mechanisms of such
a connection, obesity can be associated with changes in the
motility of the gastrointestinal tract, in particular, dysmotoria
of the stomach, due to the formation of a sense of hunger and
the regulation of the rate of digestion of food [7]. The feeling
of hunger and the intake of high calorie foods cause hormonal
imbalance through cholecystokinin, glucagon, leptin, peptide
PYY, which slows down the empty stomach and grelin, which
stimulates appetite and accelerates this function. Along with
obesity, also non-alcoholic steatohepatitis that occurs with it
can play a role in the development of motor disorders of the
colon, which are the basis of constipation [30].
Thus, the association of obesity and obstipation syndrome
is not coincidental, and this is confirmed by the fact that in
Asian countries, the association of chronic constipation with
obesity, age, and feminine gender is also observed despite the
traditionally high amount of plant food in the diet [31].
Excessive bacterial growth, chronic immune inflammation
of low activity, acceleration of transit through the proximal
small intestine can be considered among possible other mech-
anisms of association of obesity and constipation [6, 18, 20].
As a result of experimental studies, it has been shown
that in obese mice on a high-fat diet there was a decrease in
serotonin levels, one of whose functions is an increase in peri-
stalsis of the large intestine through 5-HT4 receptors, due to
the reduction of the number of enterochromatic cells in it [5].
Serotonin also plays an important role in synchronization of
the motility of various parts of the gastrointestinal tract [11],
which explains the high efficiency of 5-HT receptor agonists
in the treatment of irritable bowel syndrome [35]. Data on the
level of serotonin in the blood of patients with constipation
and obesity are heterogeneous and sometimes controversial
and studied only separately in each of them. Thus, accord-
ing to O.A.Rossyhina’s [29] studies in patients with irritable
bowel syndrome and constipation (IBSc), the serotonin con-
centration in serum was elevated, although somewhat lower
than in patients with irritable bowel syndrome with diarrhea,
and it increased after food intake, that in the author’s opin-
ion may be the cause of pain in the intestine. At the same
time, M.G. Gershon [13] determined a decrease in the concen-
tration of serotonin and enzymes of its metabolism in IBSc
and an increase in diarrhea syndrome. The literature reports
on the relationship between the degree of obesity and the
level of serotonin, leptin, grelin, endothelin-1, the index of
leptin/adiponectin and the low content of the last one [36].
Effect of serotonin on the energy homeostasis can be either
through the central regulation of food intake and through a di-
rect effect on adipose tissue [24]. It has also been established
that the serotonergic brain system plays an important role in
controlling appetite and eating behavior. Data on serotonin
level in obesity is also heterogeneous. Thus, N.V. Anikina et
al. [3] marked an increase of its level in obese women com-
pared with those in normal body weight. According to the
results of the same research of N.S. Alekseeva and co-authors
[1], the basal serotonin level in the blood of patients with
excess body weight was reduced, while after taking of easily
digestible carbohydrates and the state of emotional discomfort,
the activity of serotonergic systems increases due to increased
tryptophan insensitivity through the hematoencephalic barrier
and enhanced synthesis of serotonin, which in turn accelerates
the feeling of satiety. The consumption of food rich in car-
bohydrates stimulates the activity of serotoninergic systems
of the brain, and in case of violation of the food behavior,
their exhaustion is recorded. Reduction of serotonin level in
patients with excessive body weight has led to an increase
in the incidence of eating behavior disorders [2]. Increasing
serotonin content in obese adolescents correlates with clinical,
hormonal and psycho-emotional factors [16].
Thus, as it is seen from the published literature data, the
question of serotonin levels in patients with obesity and con-
stipation, and especially in their combination, is insufficiently
studied, and the findings are often contradictory.
The objective of research was to study changes in sero-
tonin levels in the blood of obese patients in combination with
constipation and its relationship with lipid profile of blood.
1. Materials and methods
63 patients with obesity in combination with irritable bowel
syndrome with constipation (IBSc), 24 patients with IBSc
and normal body weight and 10 practically healthy people
with normal body weight were examined. Among patients
with obesity and constipation 25 patients’ body mass index
(BMI) was 32.8±0.24 kg/m2, 28 - 37.8±1.9 kg/m2, and 10 -
42.6±0, 5 kg/m2. In patients with IBS without obesity BMI
was 21, 7±0, 4 kg/m2. In 93, 7% of examined patients with
this combined pathology, arterial hypertension of stage II also
occurred, whereas in the case of IBSc, it was diagnosed in
75.0% of patients. The IBSc diagnosis was performed accord-
ing to Rome criteria IV [17] with the degree of severity. The
frequency of defecation in patients with obesity of the first
degree was 2.0±0.1 acts, II degree - 1.5±0.1 and III degree
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- 1.4±0.2 acts per week. In patients with IBS and normal
body weight, defecation was 1.9±0.04 times a week. The
dull or colicky abdominal pains in the lateral abdomen was
occasionally found in 68.0% of patients with constipation and
obesity of the I degree, 96.4% with constipation and obesity
of the II and 60.0% with obesity of the III degree. In patients
with constipation without obesity dull pain in the abdomi-
nal flanks disturbed only 45.8% of patients. Flatulence was
noted by 64.0% of patients with obesity of the I degree and
constipation, 92.9% - of the II and 70.0% - of the III degree.
Feeling of incomplete bowel movement occurred in case of
constipation against the background of obesity of the I degree
in 56.0% of such patients, of the II degree - 71.4% and 100%
of obese subjects of the III degree. 64.0% of patients with
obesity of the I degree, 89.3% - of the II and all patients with
obesity of the III degree noted the necessity to apply their
efforts during bowel movements. In patients with IBS with
constipation without obesity the flatulence, feeling of incom-
plete defecation, the need for effort during defecation noted,
respectively, 54.2; 83.3% and 90.0% of the examined persons.
In addition to a detailed analysis of complaints and anamnesis,
evaluation of the results of endoscopic examination of the
colon and the elimination of the symptoms of the ”red flag” in
all patients with comorbid pathology and isolated IBSc, blood
serum serotonin level was determined by immune enzyme
method using ”Serotonin ELISA IBL International GMBH”
(Germany). At the same time, the study of lipid profile, in par-
ticular total cholesterol, lipoproteins of low, very low and high
density, triglycerides was performed by enzyme-colorimetric
method on the analytical modular test-system Cobas 6000
Roche Diagnostics (Switzerland). The obtained results were
statistically analyzed using the standard program package
”Statistica 8.0 for Windows” and the Microsoft Exell software
statistical function package. The probability of differences
between dependent and independent variants was estimated
using the Student’s t-criterion, and the difference was con-
sidered to be reliable in p<0.05. A pair factor correlation
analysis was also performed with the Pearson-r correlation
coefficient.
2. Results and their discussion
Table 1 shows the results of serotonin level and lipidogram
indices in patients with IBSc without obesity and in their
comorbodity in comparison both between themselves and
with analogue indeces in healthy people with normal body
weight. As one can see from the given data, in IBSc the
serotonin level in blood serum is reduced 1.6-fold (p<0.05)
compared with healthy ones. In patients with constipation
on the background of obesity of the I degree serotonin con-
centration in blood serum, on the contrary, increased 2.8-fold
(p<0.05). Such changes can probably be explained by the fact
that regulation of the contractile activity of the intestinal walls
through 5-HT signaling can occur both directly and indirectly
in constipation against the background of obesity [9]. With an
increase of body weight and an increase of blood pressure and
a severe degree of IBS with constipation, serotonin level in
blood serum was higher, respectively, 1.7-; 3.9- and 6.3-fold
more than in healthy persons (p1, 2, 3<0.05). Compared with
those in patients with IBSc without obesity, such an increase
was even more significant (2.8-, 6.3- and 10.2-fold, respec-
tively) with increasing body weight. Statistically significant
increase in serotonin concentration in blood serum in obesity
was found by other researchers, moreover, both in childhood
and adulthood [3, 40]. An elevated serotonin level in obese
patients is likely due to its association with the biological
marker of pleasure - dopamine, responsible for motivational
processes and appetite [15]. On the other hand, the intestine
is an active participant in neurohumoral regulation of eating
behavior [4, 38], and emotional discomfort that occurs with
prolonged congestion and excessive body weight contributes
to elevated levels of serotonin [39]. In addition, as a result
of overeating and intake of food with high blood protein and
carbohydrates by the obese people, the level of tryptophan, as
the main substrate for the synthesis of serotonin in the central
nervous system, increases; and as a result of insulin stimula-
tion of the tryptophan synthesis in peripheral tissues serotonin
concentration also increases the [8]. Consumption of fatty
foods, requiring less energy, does not cause a feeling of satiety,
stimulates repeated meals, inhibits intestinal peristalsis and
violates lipid metabolism in such patients. Thus, the level
of total cholesterol significantly exceeded the indicators in
healthy both in IBS without constipation and in its develop-
ment against the background of different stages of obesity,
respectively 1, 2-; 1.3-; 1.4- and 1.75-fold. The concentration
of triglycerides in the combination of IBSc against the back-
ground of obesity of the II and III degrees exceeded the similar
index in healthy persons 1.4- and 1.7-fold (p1, 2<0.05). A di-
rect correlation between high triglyceride levels and serum
serotonin concentration in obesity of the II and III degrees
and IBSc (correlation coefficients +0.68 and 0.85, p1, 2<0.05)
was determined. At the same time, there was no difference
between the level of triglycerides in patients without obesity
and the first stage of obesity (Table 1). The increase of the
degree of obesity in combination with IBSc was accompanied
by a decrease of the concentration of high-density lipoprotein
cholesterol (LDL cholesterol) at 27.7% in obesity of the II and
at 48.18% of the III degree. The level of LDL cholesterol did
not differ in patients with isolated IBSc and in its combination
with obesity of the I degree. The concentration of low density
lipoprotein (LDL) in the blood serum of patients with iso-
lated IBSc and in combination with obesity was significantly
higher than that of the healthy persons. As the body mass of
the patients with constipation increased, the concentration of
LDL cholesterol exceeded their level 1.3-fold in the healthy
persons in the obesity of the II and 1.5-fold of the III degrees.
Other researchers [1] pointed out more significant impairment
of lipidogram rates, an increase in the severity of abdomi-
nal obesity, and the progression of other components of the
metabolic syndrome in patients with a higher serum serotonin
concentration at the same time as the emotional type of eating
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Table 1. Indices of serotonin and lipid profile in blood of patients with irritable bowel syndrome with constipation and obesity.
Indicators Healthy people IBSc without
obesity
IBSc with obesity
of the I degree
IBSc with obesity
of the II degree
IBSc with obesity
of the III degree
Serotonin, ng/ml 39.13 ± 2.99
24.20 ± 1.35 67.53 ± 5.37 153.29 ± 10.98 247.09±19.78
p1 <0.05 p1 <0.05 p1<0.01 p1<0.001
p2 <0.05 p2<0.01 p2<0.001
p3<0.01 p3<0.001
4.93 ± 0.09
5.8 ± 0.2 6.2 ± 0.14 6.9 ± 0.16 8.63±0.23
Total cholesterol, p1 <0.01 p1 <0.01 p1 <0.01 p1<0.01
mmol/l p2 >0.05 p2 <0.05 p2<0.01
p3 <0.05 p3<0.001
HDLC 3.49 ± 0.23
4.17 ± 0.08 4.10 ± 0.11 4.62 ± 0.08 5.37±0.16
p1 <0.05 p1 <0.05 p1 <0.01 p1<0.01
p2 >0.05 p2 <0.01 p2<0.01
p3 <0.05 p3<0.01
LDLC 1.37 ± 0.08
1.05 ± 0.04 1.17 ± 0.05 0.99 ± 0.08 0.71±0.07
p1 <0.05 p1 <0.05 p1 <0.01 p1<0.001
p2 >0.05 p2 >0.05 p2<0.01
p3 >0.05 p3<0.05
Triglycerides 1.55 ± 0.09
1.87 ± 0.05 1.82 ± 0.06 2.17 ± 0.04 2.66±0.07
p1 <0.01 p1 <0.05 p1 <0.01 p1 <0.001
p2 >0.05 p2 <0.01 p2 <0.01
p3 <0.01 p3 <0.01
behavior. Deep violations of lipid metabolism lead to narrow-
ing of the lumen of arteries of the small and large intestines by
atheromas, fibroetheromas, reduction of contractile ability of
smooth muscle cells of arterioles, allocation of leukotrienes
in their localization zones, thromboxane A2, vasoconstriction
prostaglandins [19] and possible decrease of intestinal wall
motility. In addition, the development of constipation at a
high concentration of serotonin in patients with obesity may
be a violation of its interaction with serotonin receptors of
smooth muscles of the intestine. This is evidenced by the
absence of a physiological response from the smooth muscles
of the intestine for the administration of serotonin adipinate
in high concentrations [34].
3. Conclusions
Thus, with the increase in the degree of obesity, serotonin
level increases in blood serum, and the violation of the lipid
blood spectrum increases, which is likely to confirm the inter-
action between neurohormonal and metabolic parameters and
requires further study of such an interconnection.
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